Groundbreaking UK precision medicine project advanced targeted childhood cancer treatments
As part of a new programme to advance precision medicine in the UK, new genetic testing has enabled childhood cancer patients to receive targeted and less toxic treatments.
The first phase of the Stratified Medicine Paediatrics (SMPaeds1) programme aims to advance precision medicine for children and young people whose cancer has returned. The project focused on analysing childhood cancer tumours at diagnosis and relapse stages of the cancer journey, to help better understand how the tumours evolve.
The research team from The Institute of Cancer Research, London introduced the use of ctDNA — DNA that is released into the bloodstream circulation by cancer cells — as a potential tool for tracking cancer progression and identifying new treatment targets.
The ctDNA test offers a less invasive way to monitor how tumour mutations change over time and can add additional information that is complimentary to tissue biopsy.
Dr Sally George at the Institute of Cancer Research, London, said: “We showed that ctDNA analysis can add valuable information and that in some patients it can detect additional DNA mutations that are in the tumour but were missed by tumour biopsy.
“SMPaeds1 is the largest study with matched ctDNA and tissue sequencing to date and shows the value of ctDNA testing for children with cancer. We are working with colleagues across Europe to transition ctDNA analysis from being a research test to being available clinically.
“The project also identifies DNA mutations that become enriched at relapse. This will help us prioritise future research to understand why those mutations are enriched and if we can develop new treatments to target cancers with those mutations.”
The second phase of the research programme, SMPaeds2 – also co-funded by Children with Cancer UK and Cancer Research UK – is currently underway and aims to develop and study new tests that will build upon the success of the first phase of the programme.
SMPaeds2 will investigate blood cancers and solid tumours in children and young people, including in the brain, muscle and bone, which can be more difficult to access, diagnose and treat.
Children with Cancer UK CEO, Amar Naher, said: “We’re proud to be involved in a research project leading the way in advancing precision medicine in the UK. Children with Cancer UK’s mission is to create a world where every child and young person survives their cancer diagnosis.
“We strive to meet this mission through funding impactful research. The outcomes from the SMPaeds programmes could help in the development of targeted treatments and could lead to improved, less invasive ways of monitoring and treating childhood cancers.
By identifying genetic changes that drive relapse, the project helps advance personalised treatments, supporting the charity’s aims to improve survival rates and quality of life for young cancer patients.”
Dr Laura Danielson, children’s and young people’s research lead at Cancer Research UK, said: “We’re excited about this new research from the SMPaeds programme revealing the potential use of less invasive blood tests to better understand solid tumours in children and young people.
“These data demonstrating that analysing ctDNA could lead to a more complete picture of the tumour and how it is changing over time are incredibly important. This will pave the way for better understanding of what drives relapse or lack of response to treatment, and with it the hope of developing better, more targeted treatments.
“We’re proud to fund innovative research like this, which is unlocking new ways to study and potentially treat childhood cancers to give young cancer patients the best possible chance to live long, healthy lives.”
